Comprehensive Metabolic Phenotyping
The Comprehensive Metabolic Phenotyping (CMP) Core provides sophisticated metabolic testing in mouse models on a fee-for-service basis.
For instance, the core offers a Sable Systems Promethion metabolic caging platform for assessing food and water consumption, locomotor activity and energy expenditure; a rodent treadmill for forced exercise studies; running wheels in the Promethion system for voluntary exercise studies; a Starr Life Sciences mouse telemetry system incorporated into the Promethion; temperature-controlled cabinets for the Promethion system to conduct circadian rhythm or adaptive thermogenesis experiments; and two Seahorse systems for metabolic experiments in cells and tissues.
The core provides a series of in vivo metabolic tests, including glucose, insulin, and pyruvate tolerance test, hyperinsulinemic-euglycemic clamps to assess insulin action, hyperglycemic clamps for measuring insulin secretion, and hypoglycemic clamps for assessing gluco-counterregulation. In addition, the core can perform arterial and venous catheterizations and hepatocyte isolations. See our equipment list for more.
The core comprises expert staff and state-of-the-art equipment to perform a cadre of metabolic tests for internal and external investigators in academia and industry. The core was established in 2016 with Patrick Fueger, Ph.D., as its founding director. The core can offer new services at the request of investigators.
Comprehensive Metabolic Phenotyping (CMP) Core, directed by Patrick Fueger, Ph.D., helps investigators systematically characterize the metabolism and physiology of mouse models related to obesity, diabetes and cancer. The assays and services in the core range from routine metabolic testing to highly specialized assays using a sophisticated surgical catheterization model that permits access to the vasculature in freely moving, conscious animals. In addition, some assays require high-end instrumentation within the core. For the latter, the core offers a 16-unit Sable Systems Promethion metabolic caging platform that contains voluntary running wheels and an EchoMRI 3-in-1 system for body and tissue composition analysis. In addition, the core has all of the surgical equipment, Harvard Apparatus infusion pumps, Alpha Trak glucose monitors, and peripheral equipment for assessing insulin release in vivo with the hyperglycemic clamp technique, which is considered the platinum standard for evaluating islet function, and quantifying insulin action in vivo using the gold standard hyperinsulinemic-euglycemic clamp technique. Routine metabolic testing includes glucose, insulin and pyruvate tolerance tests and blood sampling to measure circulating hormones (e.g., insulin, C-peptide and glucagon) with ELISAs and RIAs and various metabolites (e.g., cholesterol and free fatty acids) with enzymatic assays. Finally, the core offers scientific consultation, total project management and first-pass data analysis.
Current pricing can be found on iLab Solutions.
Joan Dow
Research Associate II
jdow@coh.org
626-218-0696
Elizabeth Bloom-Saldana, M.S.
Staff Scientist
ebloomsaldana@coh.org
626-218-0696
Jose Irimia-Dominguez, Ph.D.
Staff Scientist
jidominguez@coh.org
626-218-0696
Contact the Team
Microplate washer for ELISAs
Bead homogenizer used for lyse tissues and cells for analysis of proteins and metabolites
Compact MRI unit used to measure body composition (lean, fat and water mass)
The Oroboros respirometer is used to measure cellular energetics and mitochondrial function.
Instrumented metabolic caging units used to measure mouse feeding and drinking behavior, activity, body weight, gas exchange and energy expenditure
Multiplate reader capable of measuring UV and visible absorbance, fluorescence, luminescence, fluorescence polarization for ELISAs, enzymatic assays, etc.
Vial-based alpha, beta and gamma counter used to quantify isotopic enrichment of plasma, cells and tissues
Gamma counter used for radioimmunoassays (RIAs) to quantify hormones
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
Tang, X., Miao, Y., Luo, Y., Sriram, K., Qi, Z., Lin, F. M., Gu, Y., Lai, C. H., Hsu, C. Y., Peterson, K. L., Van Keuren-Jensen, K., Fueger, P. T., Yeo, G. W., Natarajan, R., Zhong, S., & Chen, Z. B.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.
